Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Jun 23, 2025--
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'Ono') and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, MA, U.S.; CEO: Reshma Kewalramani, M.D.; 'Vertex') today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea.
Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other serious B cell-mediated diseases.
Under the terms of the agreement, Ono will pay Vertex an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications.
'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.'
'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure, and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.'
The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250623305587/en/
CONTACT: Ono Pharmaceutical Co., Ltd.
Corporate Communications
[email protected] more information:
Vertex Pharmaceuticals Incorporated
Investors:
[email protected]:
[email protected]
or
International: +44 20 3204 5275
or
U.S.: 617-341-6992
or
Heather Nichols: +1 617-839-3607
KEYWORD: NORTH AMERICA UNITED STATES SOUTH KOREA ASIA PACIFIC JAPAN MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Ono Pharmaceutical Co., Ltd.
Copyright Business Wire 2025.
PUB: 06/23/2025 04:00 AM/DISC: 06/23/2025 04:02 AM
http://www.businesswire.com/news/home/20250623305587/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Missiles, Microchips, and Money: Why Emerging Markets Just Flinched
After the U.S. struck Iran's nuclear sites over the weekend, money rushed into the dollar, pushing emerging-market currencies lower and sending investors into reassessment mode. South Korea's won was among the hardest hit in Asia, while concerns lingered around a possible disruption to the Strait of Hormuz a vital artery for global oil flows. But by Monday, Tehran hadn't moved to block it. That pause, along with a lack of immediate retaliation, may be signaling Iran's limited military options for now. Strategists at Brown Brothers Harriman noted the market reaction has been so far restrained, though the dollar could keep its safe-haven appeal if tensions flare again. Warning! GuruFocus has detected 3 Warning Signs with NIO. EM equities also took a hit. The MSCI emerging-market index fell 0.8%, with tech giants Taiwan Semiconductor and Samsung Electronics doing most of the damage. The selloff wasn't just about geopolitics a report surfaced that the U.S. Commerce Department may end key waivers that have allowed chipmakers to sell to China using American technology. That sparked the worst tech pullback in the EM benchmark since April. Tesla (NASDAQ:TSLA) and other AI-related names have been part of the recent rally in EMs, but with the AI trade now facing regulatory headwinds and regional instability, investors appear to be trimming risk without abandoning it. Still, there were signals that this isn't a full retreat. Egypt's pound and Israel's shekel actually gained, reflecting expectations that U.S. action might help cool the broader conflict. In Lebanon, defaulted sovereign bonds posted strong gains a surprise move supported by hopes of political stability and a quiet stance from Hezbollah. Meanwhile, fintech firm Valu soared on its Cairo debut, and the cost of insuring EM debt continued to decline. With the EM index still on pace for a sixth straight monthly gain, investors seem to be walking a tightrope cautious but not panicked, alert to risk but still chasing pockets of resilience. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
Core Gaming Showcases Technological Strength as AI App Gains Traction
Viral Sharing of AI COMIC on TikTok and Facebook Signals Strong User Adoption and Community Engagement User Base in Japan and South Korea Grows 1,300%, Underscoring Commercial Success and Global Potential Cutting-Edge AI Capabilities and Smart Cloud Infrastructure are Foundation for Growth VANCOUVER, BC, June 23, 2025 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that Core Gaming, a rising innovator in AI-driven creative technologies, who it recently signed a definitive merger agreement with, is experiencing continued momentum with its innovative AI COMIC app. In less than one year, combined user numbers of AI COMIC in Japan and South Korea have jumped from 2,500 to over 32,000, a 13x increase, while those countries' share of total global users rose from 4.12% to 14.38%. "AI COMIC's breakout success in Japan and South Korea is a powerful validation of our strategic vision," said Aitan Zacharin, CEO of Core Gaming. "Return on investment in the region has more than tripled, driven by targeted localization efforts such as a language-optimized user interface. Just as important, the virality we are seeing through widely used platforms like TikTok and Facebook underscores how deeply users are engaging with our product." Launched to broad interest, AI COMIC blends next-gen AI capabilities with a uniquely immersive user experience. The app empowers users to transform everyday visuals into vivid anime-style content through features such as AI-generated video, personalized avatars, manga scene recreation, time-lapse aging and realistic face swaps. Zacharin continued, "AI COMIC runs on a robust technological foundation built on our proprietary Compute Pool System, multimodal generative AI models and a scalable cloud orchestration architecture that is redefining content creation and distribution. Importantly, our goal is not just to build apps. We are building a robust, scalable AI infrastructure designed to power creative expression on a global scale. AI COMIC is only the beginning." Technology Platform: A Breakthrough AI Engine While AI COMIC continues to attract headlines and users, the underlying technology is the true differentiator. To support rapid growth and creative demand, Core Gaming built a smart, cloud- based infrastructure that delivers scalable AI performance while keeping costs efficient. This foundation enables the platform to streamline game asset creation—from automated scene and character generation to fast, high-quality animations and ad creatives—helping content teams iterate faster and bring ideas to life with minimal effort. Core Gaming's AI infrastructure is designed around three core pillars: Compute Pool System (CPS) is a dynamic AI task distribution engine that allocates computational resources across workloads in real time. CPS ensures optimal throughput for video generation, avatar rendering and real-time user interactions—without overprovisioning infrastructure. Multimodal Generative Models that process and synthesize visual, text and audio inputs simultaneously, enabling complex creative outputs such as dialogue-driven animation, mood-based styling, and high-resolution content generation tailored to the user's intent. Proprietary BigP Backend and Cloud Orchestration serves as the orchestration layer for model training, inference pipelines and content delivery. Integrated with a globally distributed cloud framework, it scales elastically to meet creative surges whether from new user spikes or major feature rollouts. "AI COMIC is just one example of what our platform can do," Zacharin continued. "Our AI infrastructure is built for scale to transform workflows across a multitude of use cases including gaming, marketing, education and enterprise content. By automating the most time-consuming parts of creation, we empower teams to focus on storytelling and strategy. The momentum we are experiencing in Japan and South Korea is a clear signal that our technology can shape the future of creative expression on a global scale." Zacharin concluded, "We continue to work diligently to finalize the merger with Siyata and remain confident that we will secure regulatory approval in the near future, with closing expected shortly thereafter." About Core Gaming, Inc. Core Gaming is an international AI driven mobile games developer and publisher headquartered in Miami. We create entertaining games for millions of players worldwide, while empowering other developers to deliver player-focused apps and games to enthusiasts. Core's mission is to be the leading global AI driven gaming company. Since our launch we have developed and co-developed over 2,100 games, driven over 780 million downloads, and generated a global footprint of over 40 million users from over 140 countries. Visit to learn more. About Siyata Mobile Inc. Siyata Mobile Inc. is a B2B global developer and vendor of next-generation Push-To-Talk over Cellular handsets and accessories. Its portfolio of rugged PTT handsets and accessories enables first responders and enterprise workers to instantly communicate over a nationwide cellular network of choice, to increase situational awareness and save lives. Police, fire, and ambulance organizations as well as schools, utilities, security companies, hospitals, waste management companies, resorts and many other organizations use Siyata PTT handsets and accessories today. In support of our Push-to-Talk handsets and accessories, Siyata also offers enterprise-grade In- Vehicle solutions and Cellular Booster systems enabling our customers to communicate effectively when they are in their vehicles, and even in areas where the cellular signal is weak. Siyata sells its portfolio through leading North American cellular carriers, and through international cellular carriers and distributors. Siyata's common shares trade on the Nasdaq under the symbol "SYTA", and its common warrants trade on the Nasdaq under the symbol "SYTAW". Visit to learn more. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Siyata's filings with the Securities and Exchange Commission ("SEC"), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release. View original content to download multimedia: SOURCE Siyata Mobile Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Quanterix Expands Reach with IVD and Large Reference Labs
Simoa Technology Advances Earlier Disease Detection by Measuring Signature Biomarkers BILLERICA, Mass., June 23, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems. The continued expansion of the industry-leading Simoa® technology platform into global markets demonstrates a key milestone in broadening validation of biomarker-based testing and providing clinicians with minimally invasive tools that can help enhance diagnostic accuracy and improve accessibility. Through its unparalleled sensitivity and multi-marker testing capability, the Simoa platform delivers ultrasensitive biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ) of traditional measurement platforms. "Quanterix is the only platform in the neurodegenerative space that can be used in research to discover a biomarker, power an endpoint in a clinical trial and progress to a diagnostic test," said Masoud Toloue, Chief Executive Officer at Quanterix. "Other instruments only address narrow use cases, as they are either only high-plex discovery orientated or diagnostic use only. Quanterix makes discovery to diagnostics happen by powering a critical step in between, biopharma clinical trials. As a result, our ultra-sensitive Simoa technology serves as the backbone for many of the Alzheimer's tests coming to the market today." Quanterix has established several new global collaborations with laboratories and patient testing centers, further strengthening the infrastructure for Alzheimer's testing and reinforcing its clinical utility. These recent collaborations include: ARUP Laboratories - a leading national reference laboratory that recently launched a blood test for phosphorylated tau 217 (P-tau217) to assist in identifying whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer's disease (AD) pathology. ARUP's test will be performed on Quanterix's SP-X® platform with the Quanterix Simoa® assay kit, which uses P-tau217 antibody technology licensed from Eli Lilly and Company. Neurogen Biomarking – the world's first ecosystem for memory loss with end-to-end patient support recently announced an easy-to-use at-home blood biomarker collection test that can measure phosphorylated tau 217 (P-tau217), a specific marker for Alzheimer's disease pathology and MCI, using Quanterix's highly sensitive technology. NSW Health Pathology – the largest public pathology service in Australia, has validated NfL for patient testing. Rede D'Or, Richet Laboratory (IDOR) – the largest integrated health care network in Brazil, covering over 70 hospitals, was the first Brazilian institution to acquire a Simoa HD-X and implement both P-tau217 and NfL for testing. IDOR recently published their first paper in Nature Communications on their work to reduce the underdiagnosis of AD in Brazil. According to research, early signs of Alzheimer's disease (AD) may begin 20 years or more before symptoms appear. The Simoa platform equips customers with advanced insights to help accelerate their research and diagnosis, along with accelerating early detection during this crucial timeframe, allowing patients expanded access to treatments that are not available once the disease has progressed to an advanced stage. "Our team works primarily on Alzheimer's Disease and dementia, so from day one, our focus has been on reporting how Simoa biomarkers perform when detecting amyloid status and cognitive decline in a local sample," said Luis Eduardo da Silva Santos, Scientist, Rede D'Or Institute for Research and Education. "IDOR was the first Brazilian institution to acquire a Simoa HD-X and we are excited to see that our work, published in Nature Communications, is now serving as the basis for the local implementation of two Simoa kits, P-tau217 ALZpath and NfL. We expect these tests to be more affordable than current alternatives and to contribute to reducing the underdiagnosis of AD in Brazil." For more information on the Simoa platform, visit About QuanterixFrom discovery to diagnostics, Quanterix's ultrasensitive biomarker detection fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@
